department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

CytomX Therapeutics, Inc. ($CTMX) · pharmadog

PUBLIC COMPANY

$CTMXCytomX Therapeutics, Inc.

South San Francisco, CA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

2Phase 1

Head And Neck Squamous Cell Carcinoma (HNSC)

varsetatug masetecan

Epithelial Tumor

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view CytomX Therapeutics, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$CTMX

SEC CIK

0001501989

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

Data sources

last refreshed just now

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$CTMX

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase1First In Human Study of CX-801 in Advanced Solid Tumorsrecruitingn=121
phase1First In Human Study of CX-2051 in Advanced Solid Tumorsrecruitingn=160
phase2PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumorsterminatedn=3
phase1A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumorsterminatedn=83
phase2PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomasterminatedn=196
phase2Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancercompletedn=125
phase2PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCLcompletedn=133
phase2PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumorsterminatedn=99

more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

Mar 17, 26SELLMcCarthy Sean A.· CEO118,969 sh @ $6.42−$764K↗
Mar 17, 26SELLBELVIN MARCIA· SVP, Chief Scientific Officer31,492 sh @ $6.42−$202K↗
Mar 17, 26SELLChu Yu-Waye· Chief Medical Officer21,279 sh @ $6.42−$137K↗
Mar 17, 26SELLOgden Christopher· Chief Financial Officer19,323 sh @ $6.42−$124K↗

routine RSU / option mechanics (6)

Feb 2, 26grantChu Yu-Waye · Chief Medical Officer75,000 sh
Feb 2, 26grantChu Yu-Waye · Chief Medical Officer300,000 sh
Feb 2, 26grantBELVIN MARCIA · SVP, Chief Scientific Officer60,000 sh
Feb 2, 26grantBELVIN MARCIA · SVP, Chief Scientific Officer250,000 sh
Feb 2, 26grantOgden Christopher · Chief Financial Officer90,000 sh

Feb 2, 26

grant

Ogden Christopher · Chief Financial Officer

325,000 sh